{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458269502
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[Interleukin 4|IL-4]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 331243-22-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| IUPHAR_ligand = 7786
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = N1IOA09R6A
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Pascolizumab''' is a [[humanized monoclonal antibody]] for the treatment of [[asthma]].<ref>{{cite journal|pmid=12296858|year=2002|last1=Hart|first1=TK|last2=Blackburn|last3=Brigham-Burke|last4=Dede|last5=Al-Mahdi|last6=Zia-Amirhosseini|last7=Cook|title=Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma|volume=130|issue=1|pages=93â€“100|journal=Clinical and experimental immunology|doi=10.1046/j.1365-2249.2002.01973.x|first2=MN|first3=M|first4=K|first5=N|first6=P|first7=RM|pmc=1906490}}</ref> A Phase II [[clinical trial]] in patients with symptomatic [[glucocorticoid]] naive asthma has been conducted in 2001/2002.<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00024544 ClinicalTrials.gov]</ref>

==References==
{{Reflist}}

{{Immunosuppressants}}
{{Monoclonals for immune system}}
{{Interleukin receptor modulators}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}